Eli Lilly and Co

🇺🇸United States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials
Related News

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Phase 2
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
First Posted Date
2005-09-19
Last Posted Date
2006-07-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
50
Registration Number
NCT00191841
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ufa, Russian Federation

A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

First Posted Date
2005-09-19
Last Posted Date
2011-08-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
502
Registration Number
NCT00190775
Locations
🇵🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, Puerto Rico

2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

Phase 4
Completed
Conditions
Osteoporosis, Postmenopausal
First Posted Date
2005-09-19
Last Posted Date
2007-07-16
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
810
Registration Number
NCT00191425
Locations
🇩🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Pyrmont, Germany

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC

First Posted Date
2005-09-19
Last Posted Date
2019-09-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
263
Registration Number
NCT00191126
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician., Taichung, Taiwan

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

First Posted Date
2005-09-19
Last Posted Date
2011-03-04
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
919
Registration Number
NCT00191646
Locations
🇵🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer

First Posted Date
2005-09-19
Last Posted Date
2011-02-07
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
84
Registration Number
NCT00192075
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States

A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

First Posted Date
2005-09-19
Last Posted Date
2011-01-05
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
46
Registration Number
NCT00191984
Locations
🇫🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Suresnes, France

Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)

First Posted Date
2005-09-19
Last Posted Date
2010-12-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
228
Registration Number
NCT00191386
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wakayama, Japan

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

Phase 3
Completed
Conditions
Failure to Thrive
First Posted Date
2005-09-19
Last Posted Date
2010-12-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
75
Registration Number
NCT00190658
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States

Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer

First Posted Date
2005-09-19
Last Posted Date
2010-12-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
49
Registration Number
NCT00192036
Locations
🇧🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turnhout, Belgium

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy